Dr. Mahwash Kamal, MD

Dr. Kamal practices at Vanderbilt Bedford Hospital in Shelbyville, Tennessee, part of Vanderbilt University Medical Center.

Dr. Kamal's NPI, 1104112283, was assigned on June 27, 2011. Dr. Kamal holds Tennessee license 55723.

Dr. Kamal's primary practice is Vanderbilt Bedford Hospital, at 2835 Hwy 231 North, Shelbyville, TN 37160 in Bedford County. The practice phone is (931) 685-5433.

Dr. Kamal's primary practice is Vanderbilt Bedford Hospital in Shelbyville, Tennessee, part of Vanderbilt University Medical Center. Dr. Kamal is also affiliated with Saint Francis Hospital-Memphis. The medical group on file is Vanderbilt University Medical Center. Dmand AI also links Dr. Kamal to 1 more physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kamal practices, 4 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Kamal's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Kamal is board certified in internal medicine by the American Board of Internal Medicine. Dr. Kamal is licensed in Tennessee.

CMS data shows 356 Medicare services from Dr. Kamal across 5 procedure codes in 2024, for 89 Medicare patients. Medicare paid $24,524 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 89 Medicare patients who saw Dr. Kamal in 2024. The largest group is 65 to 74, with 38 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 37% are also on Medicaid. Their average risk score is 4.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kamal's median patient age at 61, with 43% women.

In 2020, Dr. Kamal wrote 42 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $385 in total drug cost. In 2019, CMS named 26 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Kamal for performance year 2024, reported as part of a group. Dr. Kamal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kamal as offering telehealth.

CMS Open Payments shows 6 general payments to Dr. Kamal from 5 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 57% of the total. Astellas Pharma US Inc paid the most, $73.